ARIH1 Inhibitors
RIH1 inhibitors belong to a class of compounds designed to target and modulate the activity of the E3 ubiquitin-protein ligase ARIH1, also known as TRIAD1. ARIH1, an enzyme encoded by the ARIH1 gene, plays a crucial role in the ubiquitin-proteasome system, a cellular pathway responsible for the regulated degradation of proteins. Specifically, ARIH1 functions as an E3 ubiquitin ligase, facilitating the transfer of ubiquitin molecules onto substrate proteins, marking them for subsequent degradation by the proteasome. Inhibitors of ARIH1 aim to selectively interfere with its enzymatic activity, disrupting the ubiquitination process and thereby modulating the degradation of specific target proteins.
The development of ARIH1 inhibitors has gained significance due to the growing understanding of the ubiquitin-proteasome system's central role in cellular homeostasis and protein quality control. By selectively inhibiting ARIH1, these compounds hold the potential to influence various cellular processes and pathways associated with protein turnover. This class of inhibitors typically involves small molecules that interact with the active site or other critical regions of ARIH1, disrupting its catalytic function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib inhibits the 26S proteasome, thereby affecting the degradation of ubiquitinated proteins, which can alter ARIH1-mediated ubiquitination outcomes. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 is a proteasome inhibitor that can prevent the degradation of ubiquitin-conjugated proteins, potentially influencing ARIH1's regulatory functions. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
Carfilzomib is another proteasome inhibitor that can disrupt the degradation pathway of ubiquitinated proteins, indirectly affecting ARIH1 activity. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
MLN4924 inhibits the NEDD8-activating enzyme, which is crucial for ubiquitin ligase activity, thus it can indirectly affect ARIH1's function. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin is a specific inhibitor of the proteasome, which can modify the turnover of proteins regulated by ARIH1 ubiquitination. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin is a selective proteasome inhibitor, which could lead to an accumulation of ARIH1 substrates. | ||||||
IU1 | 314245-33-5 | sc-361215 sc-361215A sc-361215B | 10 mg 50 mg 100 mg | $138.00 $607.00 $866.00 | 2 | |
IU1 inhibits the deubiquitinase USP14, which can influence ubiquitin dynamics and potentially ARIH1's role in ubiquitination. | ||||||
Ubiquitin E1 Inhibitor, PYR-41 | 418805-02-4 | sc-358737 | 25 mg | $360.00 | 4 | |
PYR-41 is an irreversible inhibitor of ubiquitin-activating enzyme E1, which can indirectly modulate ARIH1's ubiquitin ligase activity. | ||||||
Withaferin A | 5119-48-2 | sc-200381 sc-200381A sc-200381B sc-200381C | 1 mg 10 mg 100 mg 1 g | $130.00 $583.00 $4172.00 $20506.00 | 20 | |
Withaferin A has been shown to inhibit the proteasomal activity, thereby potentially altering the protein ubiquitination process linked with ARIH1. | ||||||